ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $2.21, $0.18 better than the analyst estimate of $2.03. Revenue for the quarter came in at $266 million versus the consensus estimate of $262.14 million.

FY 2026 Outlook:-

Revenue between $1.08 billion to $1.14 billion vs consensus $1.12 billion.
EPS between $9.19 to $9.69 vs consensus $9.42.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.